AL001 ( DrugBank: AL001 )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
| 127 | Frontotemporal lobar degeneration | 15 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05053035 (ClinicalTrials.gov) | September 2, 2021 | 1/9/2021 | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in C9orf72-Associated Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: AL001;Drug: Placebo | Alector Inc. | NULL | Active, not recruiting | 18 Years | N/A | All | 45 | Phase 2 | United States |
127. Frontotemporal lobar degeneration
Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004066-18-FR (EUCTR) | 04/02/2021 | 30/06/2020 | A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: not available Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | United States;Portugal;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden | ||
| 2 | EUCTR2019-004066-18-GB (EUCTR) | 03/12/2020 | 25/09/2020 | A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: not available Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | Portugal;United States;Spain;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden | ||
| 3 | EUCTR2019-004066-18-SE (EUCTR) | 06/10/2020 | 10/06/2020 | A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: Latozinemab Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | United States;Portugal;Spain;Italy;United Kingdom;Switzerland;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden | ||
| 4 | EUCTR2019-004066-18-NL (EUCTR) | 02/09/2020 | 03/03/2020 | A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: not available Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | United States;Portugal;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;Netherlands;Germany;Sweden | ||
| 5 | EUCTR2019-004066-18-BE (EUCTR) | 31/07/2020 | 26/05/2020 | A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: Latozinemab Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | United States;Portugal;Spain;Italy;United Kingdom;Switzerland;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden | ||
| 6 | NCT04374136 (ClinicalTrials.gov) | July 23, 2020 | 23/4/2020 | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene | Frontotemporal Dementia | Drug: AL001;Drug: Placebo;Drug: Open label - AL001 | Alector Inc. | NULL | Recruiting | 25 Years | 85 Years | All | 180 | Phase 3 | United States;Argentina;Australia;Belgium;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom |
| 7 | EUCTR2019-004066-18-DE (EUCTR) | 06/07/2020 | 20/02/2020 | A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: Latozinemab Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | Portugal;Spain;Italy;United Kingdom;Switzerland;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden;United States | ||
| 8 | EUCTR2019-004066-18-PT (EUCTR) | 29/05/2020 | 21/02/2020 | A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: not available Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | Portugal;United States;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;Germany;Netherlands;Sweden | ||
| 9 | EUCTR2019-004066-18-IT (EUCTR) | 18/05/2020 | 15/06/2021 | A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD. | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene. - NA | Frontotemporal Dementia. MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: [AL001] INN or Proposed INN: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | Germany;Netherlands;Sweden;United States;Portugal;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia | ||
| 10 | EUCTR2019-004066-18-ES (EUCTR) | 22/04/2020 | 06/03/2020 | A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: not available Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | United States;Portugal;France;Canada;Belgium;Spain;Australia;Netherlands;Germany;United Kingdom;Italy;Sweden | ||
| 11 | EUCTR2019-000138-20-GB (EUCTR) | 18/11/2019 | 21/05/2019 | An Open-Label Study to Evaluate Safety of long-term AL001 dosing in FTD | A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: not available Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 32 | Phase 2 | United States;Canada;Netherlands;Germany;Italy;United Kingdom | ||
| 12 | EUCTR2019-000138-20-DE (EUCTR) | 08/10/2019 | 27/05/2019 | An Open-Label Study to Evaluate Safety of long-term AL001 dosing in FTD | A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9orf72 Mutations Causative of Frontotemporal Dementia | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: Latozinemab Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | United States;Canada;Netherlands;Germany;United Kingdom;Italy | ||
| 13 | EUCTR2019-000138-20-IT (EUCTR) | 24/09/2019 | 15/01/2021 | An Open-Label Study to Evaluate Safety of long-term AL001 dosing in FTD | A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia - - | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: [AL001] | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 32 | Phase 2 | United States;Canada;Netherlands;Germany;United Kingdom;Italy | ||
| 14 | EUCTR2019-000138-20-NL (EUCTR) | 20/09/2019 | 06/06/2019 | An Open-Label Study to Evaluate Safety of long-term AL001 dosing in FTD | A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9orf72 Mutations Causative of Frontotemporal Dementia | Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AL001 Product Code: AL001 INN or Proposed INN: not available Other descriptive name: AL001 | Alector Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | United States;Canada;Germany;Netherlands;United Kingdom;Italy | ||
| 15 | NCT03636204 (ClinicalTrials.gov) | September 14, 2018 | 12/7/2018 | A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation | A First in Human Phase 1 Study in Healthy Volunteers and in Participants With Frontotemporal Dementia (FTD) With Granulin Mutation | Healthy;Frontotemporal Dementia | Biological: AL001;Other: Placebo | Alector Inc. | NULL | Completed | 18 Years | 80 Years | All | 64 | Phase 1 | United States;Canada;United Kingdom;Netherlands |